Carregant...
The Immune Response to the fVIII Gene Therapy in Preclinical Models
Neutralizing antibodies to factor VIII (fVIII), referred to as “inhibitors,” remain the most challenging complication post-fVIII replacement therapy. Preclinical development of novel fVIII products involves studies incorporating hemophilia A (HA) and wild-type animal models. Though immunogenicity is...
Guardat en:
| Publicat a: | Front Immunol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7174743/ https://ncbi.nlm.nih.gov/pubmed/32351497 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.00494 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|